TG Therapeutics, Inc. Financials

Market Capitalization $5.83 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	146.88
Forward PE	37.86
Price to Sales TTM	$15.09
Price to Book MRQ	$22.47
Enterprise to Revenue	13.53
Enterprise to EBITDA	87.30

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	10.13%
Operating Margin	7.13%
Return on Assets TTM	7.26%
Return on Equity TTM	19.70%

Income Statement

Revenue TTM	$386,385,984
Revenue per Share TTM	$2.66
Quarterly Revenue Growth	90.40%
Gross Profit TTM	$337,800,000
EBITDA	$70,621,000
Net Income to Common TTM	$39,150,000
Diluted EPS TTM	$0.25
Quarterly Earnings Growth YoY	90.40%

Balance Sheet

Total Cash MRQ	$276,240,000
Total Cash per Share MRQ	$1.89
Total Debt MRQ	$
Total Debt to Equity MRQ	107.29
Current Ratio MRQ	4.02
Book Value per Share MRQ	$1.63

Cash Flow

Operating Cash Flow TTM	$-61,025,000
Levered Free Cash Flow TTM	$-87,638,496

TGTX Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	155,836,256
Float Shares	135,060,602
Avg 10 Volume	1,555,660
Avg 30 Volume	None
Shares Short	23,697,171
Short Ratio	13.21
Short % of Shares	19.52%
% Held by Insiders	9.74%
% Held by Institutions	63.24%

Stock Price Summary

Beta	1.94
Fifty Two Week Low	$16.65
Fifty Two Week High	$46.48
Fifty Two Week Change	48.23%
Day 50 MA	$37.04
Day 200 MA	$32.69

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2012-04-30